Repligen Corporation

Financials

Flujo de caja de las actividades operativas 39.18 M15.01 M28.61 M48.1 M25.7 M 117.42 M Flujo de caja de las actividades de inversión -64.76 M-74.11 M-7.84 M-7.78 M-208.74 M -298.47 M Flujo de caja de las actividades financieras 1.45 M-5.03 M-10.13 M-239 K195 K -15.21 M Flujo de caja libre 32.19 M10.57 M21 M42.71 M17.39 M 91.69 M

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

RGEN

Financials

Repligen Corporation

Noticias

Repligen: Advancing, Yet Much More Work Ahead (NASDAQ:RGEN)

Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?

H.C. Wainwright eleva el precio objetivo de Repligen por su fuerte crecimiento

Evercore prevé crecimiento del gasto en biofarmacéutica según encuesta

Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Repligen en la Conferencia Leerink: Crecimiento Estratégico y Desafíos

Repligen en Conferencia Leerink: Crecimiento Estratégico y Desafíos

Repligen at Leerink Conference: Strategic Growth and Challenges

Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript

KeyBanc reitera calificación de acciones de Repligen por impulso de productos

KeyBanc reiterates Repligen stock rating on product momentum

Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y